real-time news and commentary for investors
Wednesday, Dec 5
2012, 7:28 PM
Delcath Systems (DCTH) says it's seeking FDA approval for a narrower use than originally...
Delcath Systems (DCTH) says it's seeking FDA approval for a narrower use than originally expected for its new liver cancer drug, based on the agency's guidance. The company said it's now seeking to focus its new chemosaturation system on just treating patients with inoperable metastatic ocular melanoma in the liver, a rare form of cancer that generally begins as a melanoma of the eye, rather than to use the drug to treat other forms of melanoma in the liver as well. Shares -11% AH.